

Listing of Claims:

1. (Currently Amended) A process for the preparation of form + I of olanzapine, comprising the step of crystallizing olanzapine in a solvent mixture which comprises 2-propanol.
2. (Original) Process according to claim 1, wherein the solvent mixture also comprises at least one further solvent selected from group consisting of tetrahydrofuran, methylene chloride, acetone, toluene, N, N-dimethylformamide, dimethylsulfoxide, and chloroform.
3. (Original) Process according to claim 2, wherein the solvent mixture comprises 2-propanol and at least one further solvent in a ratio of 1:0.1 to 5 parts by volume.
4. (Currently Amended) Process according to claim 1, wherein the ~~olanzapine~~ olanzapine is used in form of a solvate of olanzapine.
5. (Original) Process according to claim 4, wherein the solvate is at least one of the group consisting of a methylene chloride solvate, a 2-propanol solvate, a acetonitrile/methylene chloride/water mixed solvate and acetonitrile/water mixed solvate of olanzapine.
6. (Original) Acetonitrile/methylene chloride/water mixed solvate of olanzapine characterized by an x-ray powder diffraction pattern (2 theta) as follows:
8.76, 19.39, 20.12.
7. (Original) Acetonitrile/methylene chloride/water mixed solvate of olanzapine according to claim 6, characterized by an x-ray powder diffraction pattern (2 theta) as follows:
8.76, 18.29, 19.39, 19.66, 20.12, 23.13, 23.62, 25.08.
8. (Original) Acetonitrile/water mixed solvate of olanzapine characterized by an x-ray powder diffraction pattern (2 theta) as follows:
8.76, 9.10, 14.05, 19.37, 20.10, 24.55, 25.92, 27.96.

9. (Original) Acetonitrile/water mixed solvate of olanzapine according to claim 8, characterized by an x-ray powder diffraction pattern (2 theta) as follows:

8.76, 9.10, 14.05, 14.44, 18.30, 18.67, 18.84, 19.37, 19.68, 20.10, 20.54, 21.65, 22.79, 23.12, 23.62, 24.55, 25.06, 25.92, 27.96, 28.44.

10. (Original) 2-propanol solvate of olanzapine characterized by an x-ray powder diffraction pattern as follows:

8.74, 14.05, 19.38, 22.65, 23.03, 24.46, 25.92, 28.36.

11. (Currently Amended) 2-propanol solvate of ~~olanzpine~~ olanzapine according to claim 10, characterized by an x-ray powder diffraction pattern as follows:

8.74, 14.05, 14.41, 17.77, 18.22, 18.76, 19.38, 19.81, 19.95, 20.54, 20.96, 21.64, 22.26, 22.65, 23.03, 23.58, 23.90, 24.46, 25.03, 25.39, 25.92, 26.63, 27.47, 27.95, 28.36.

12. (Original) Methylene chloride solvate IA of olanzapine characterized by an x-ray powder diffraction pattern as follows:

10.80, 14.25, 19.22, 22.78, 24.53.

13. (Original) Methylene chloride solvate IA of olanzapine according to claim 12, characterized by an x-ray powder diffraction pattern as follows:

8.85, 10.80, 12.89, 14.09, 14.25, 18.37, 18.81, 19.22, 19.41, 19.57, 20.07, 20.80, 21.00, 21.71, 22.06, 22.25, 22.78, 23.14, 23.62, 24.03, 24.53, 25.04, 25.43, 26.67, 27.51, 28.00, 28.45, 28.70.

14. (Original) Methylene chloride solvate IB of olanzapine characterized by an x-ray powder diffraction pattern as follows:

9.30, 10.80, 14.25, 14.98, 15.94, 19.23, 20.04.

15. (Currently Amended) Methylene chloride solvate IB of ~~olazapine~~ olanzapine according to claim 14, characterized by an x-ray powder diffraction pattern as follows:

8.43, 8.86, 9.30, 10.80, 14.25, 14.98, 15.94, 16.88, 17.79, 18.40, 18.57, 18.83, 19.23, 19.57, 20.04, 20.79, 21.01, 21.68, 22.06, 22.23, 23.57, 24.02, 24.89, 25.12, 25.46, 26.38, 26.56, 27.50, 28.06, 28.71, 29.02.

16. (Previously Presented) Process for preparing anhydrous forms of olanzapine by drying at least one solvate according to claim 6.

17. (Previously Presented) Process wherein the anhydrous form I of olanzapine is prepared by drying at least one solvate according to claim 12.

18. (Original) Form A of olanzapine characterized by an x-ray powder diffraction pattern as follows:

11.52, 12.00, 13.35, 13.56, 14.21, 15.47, 16.69, 19.16, 20.25 20.69, 22.12, 24.33, 26.88, 27.13.

19. (Original) Form A of olanzapine according to claim 18, characterized by an x-ray powder diffraction pattern as follows:

11.52, 11.83, 12.00, 13.35, 13.56, 14.21, 15.47, 16.69, 17.83, 19.16, 20.25, 20.69, 21.65, 22.12, 23.21, 24.33, 26.88, 27.13, 28.57.

20. (Previously Presented) Form A of olanzapine according to claim 18, which is in essential pure form.

21. (Previously Presented) Form A of olanzapine according to claim 18, which is anhydrous.

22. (Previously Presented) Process for preparing form A of olanzapine as defined in claim 18, comprising the steps of dissolving any form of olanzapine in a mixture of acetonitrile with a solvent in which olanzapine is soluble or in a solvent in which olanzapine is soluble, heating the mixture to obtain a clear solution, optionally filtering the solution, partly evaporating the solvent and isolating the product.

23. (Previously Presented) Pharmaceutical composition which comprises form A of olanzapine according to claim 18.

24. (Previously Presented) Process for preparing anhydrous forms of olanzapine by drying at least one solvate according to claim 8.

25. (Previously Presented) Process for preparing anhydrous forms of olanzapine by drying at least one solvate according to claim 10.

26. (Previously Presented) Process for preparing anhydrous forms of olanzapine by drying at least one solvate according to claim 12.

27. (Previously Presented) Process for preparing anhydrous forms of olanzapine by drying at least one solvate according to claim 14.

28. (Previously Presented) Process wherein the anhydrous form I of olanzapine is prepared by drying at least one solvate according to claim 14.